Navigation Links
Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Date:10/15/2007

COLLEGEVILLE, Pa., Oct. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), reported that new study data presented today at the 63rd Annual Meeting of the American Society for Reproductive Medicine (ASRM) showed that women who received 100 mg/day or 150 mg/day of desvenlafaxine, a serotonin and norepinephrine reuptake inhibitor (SNRI), experienced a significant reduction in moderate to severe vasomotor symptoms (VMS) (hot flashes and night sweats) associated with menopause over those taking placebo. This significant reduction was seen as early as week one.

The common adverse drug reactions (greater than or equal to five percent of either desvenlafaxine group) in this study were asthenia, hypertension, anorexia (loss of appetite), constipation, diarrhea, dry mouth, nausea, dizziness, insomnia, somnolence and mydriasis.

"There are more than 10 million menopausal women who experience moderate to severe hot flashes and night sweats. Only a small percentage of menopausal women use FDA-approved treatments, all of which are hormone-based," says Ginger Constantine, M.D., Vice President, Women's Health Care, Wyeth Pharmaceuticals. "Wyeth is committed to continuing to develop desvenlafaxine as a potential non-hormonal treatment option for women with moderate to severe vasomotor symptoms associated with menopause."

In July 2007, Wyeth received an approvable letter from the FDA for desvenlafaxine in the treatment of moderate to severe vasomotor symptoms associated with menopause. Wyeth is working with the FDA to address several items in the letter and to gain agreement on the design of one additional safety study. The efficacy and safety data for desvenlafaxine presented at the me
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Md. and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Roger Jeffs , ... provide an overview and update on the company,s business at ... in Boston, Massachusetts . The ... 3:30 PM Eastern Time, and can be accessed via a ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
(Date:4/30/2015)... South San Francisco, CA (PRWEB) April 30, 2015 ... revenues for the first quarter of 2015 were $4.4 million, ... The net loss for the first quarter was $8.9 ... compared to a net loss for the same period in ... diluted share. As of March 31, 2015, cash, cash equivalents ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Europe Trails in Expanded IIIP Innovation Confidence Index , ... San Francisco, ... was largely unaffected by the drop in consumer confidence last year, according ... to cover every region of the world and released publicly today. ...
... at the U.S. Department of Energy (DOE) Joint Genome Institute ... analysis of the complete genome of sorghum, a major food ... The genome data will aid scientists in optimizing sorghum ... but also for biofuels production. The comparative analysis of ...
... Endo Pharmaceuticals Inc. (Nasdaq: ENDP ), ... results on February 27, 2009 and will host ... that day to discuss these results. David P. ... Chief Operating Officer and Blaine Davis, Vice President, Corporate ...
Cached Biology Technology:Global Confidence in Innovation Holds Despite Economy 2Global Confidence in Innovation Holds Despite Economy 3Global Confidence in Innovation Holds Despite Economy 4Scientists publish complete genetic blueprint of key biofuels crop 2Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009 2
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... York, NY) The Parkinson,s Disease Foundation (PDF) is pleased ... the potential of individualized stem cell therapy to treat ... research of Marina Emborg, M.D., Ph.D., and Su-Chun Zhang, ... This award was chosen as part of PDF,s ...
... DCGeorgetown University Medical Center and Oak Ridge ... the institutions that formalizes their research relationship ... in the areas of structural biology, systems ... The Comprehensive Research and Development Agreement ...
... 23, 2008 -- Eight Oak Ridge National Laboratory nanomanufacturing ... Department of Energy,s Industrial Technologies Program. The awards, ... $1.6 million to partners, are the result of a ... The awards are for the following projects: ...
Cached Biology News:Parkinson's Disease Foundation announces award of $150,000 2GUMC and Oak Ridge National Labs announce unique research partnership 2GUMC and Oak Ridge National Labs announce unique research partnership 3ORNL nanotechnologies big winners in DOE call 2ORNL nanotechnologies big winners in DOE call 3
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
PPIF Antibody...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Biology Products: